Sanofi, which acquired Genzyme in 2011, responded to the findings, stating it is "fully committed to resolving all issues holistically and promptly." A company spokesperson emphasized that manufacturing operations and drug supplies remain uninterrupted, even as Sanofi works to align with FDA requirements. The Framingham site plays a key role in Sanofi's operations, particularly in producing therapies for rare diseases and other critical areas.